INmune Bio, Inc.
INMB
$7.30
-$0.20-2.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.56% | -4.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.15% | -22.94% | |||
| Operating Income | -4.63% | 22.94% | |||
| Income Before Tax | -5.65% | 23.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.65% | 23.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.65% | 23.77% | |||
| EBIT | -4.63% | 22.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.46% | 30.83% | |||
| Normalized Basic EPS | -4.48% | 30.82% | |||
| EPS Diluted | -4.46% | 30.83% | |||
| Normalized Diluted EPS | -4.48% | 30.82% | |||
| Average Basic Shares Outstanding | 1.12% | 10.21% | |||
| Average Diluted Shares Outstanding | 1.12% | 10.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||